GleamWall
中文EN

NMTC NEUROONE MEDICAL TECHNOLOGIES Corp

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1500198 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY42.8%
TTM net income YoY-39.5%
TTM EPS YoY-20.9%
Revenue 3-yr CAGR94.9%
Net income 3-yr CAGR—

Margins

Gross margin55.6%
Operating margin-83.4%
Net margin-78.6%
FCF margin-75.6%
EBITDA margin-81.0%

Returns

ROE-124.7%
ROA-87.6%
ROIC (approx.)-671.9%
Asset turnover1.11x

Leverage & solvency

Liabilities / assets39.1%
Debt / equity0.00x
Current ratio2.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-06-302026Q22026-03-312026Q12025-12-312025Q4*2025-09-302025Q32025-06-302025Q22025-03-312025Q12024-12-312024Q4*2024-09-30
Income statement
Revenue$1.97M$1.86M$2.89M$2.74M$1.70M$1.39M$3.27M$272,284
Cost of revenue$790,496$871,786$1.32M$1.21M$781,215$615,489$1.35M$131,222
Gross profit$1.18M$990,264$1.57M$1.53M$914,835$771,061$1.93M$141,062
R&D expense$1.43M$1.47M$1.39M$1.12M$1.18M$1.51M$1.17M$1.11M
SG&A expense$2.18M$1.92M$1.89M$1.78M$1.62M$1.94M$2.04M$1.84M
Operating income-$2.42M-$2.40M-$1.71M-$1.37M-$1.89M-$2.68M$1.71M-$2.82M
Pretax income-$2.01M-$2.38M-$1.44M-$1.62M-$1.50M-$2.27M$1.79M-$3.35M
Net income-$2.01M-$2.38M-$1.44M-$1.62M-$1.50M-$2.27M$1.79M-$3.35M
EBITDA-$2.38M-$2.34M-$1.64M-$1.31M-$1.83M-$2.62M$1.78M-$2.75M
EPS (basic)-0.23-0.28-0.03—-0.19-0.440.06—
EPS (diluted)-0.28-0.28-0.03—-0.19-0.440.06—
Weighted avg. shares (diluted)8.74M8.48M50.33M—8.10M5.19M30.88M—
Balance sheet
Cash & equivalents$2.05M$2.80M$3.56M$6.57M$8.04M$1.32M$1.13M$1.46M
Receivables$1.10M$1.90M$2.66M$1.26M—$318,780$2.37M$176,636
Inventory$2.29M$2.10M$1.67M$2.23M$1.90M$1.83M$1.93M$2.64M
Current assets$5.79M$7.11M$8.07M$10.23M$10.17M$3.75M$5.71M$4.63M
PP&E, net$202,333$230,596$244,906$259,222$314,588$334,853$381,711$416,843
Intangibles$28,210$33,789$39,368$44,946$50,525$56,104$61,683$67,262
Total assets$6.19M$7.57M$8.58M$10.79M$10.82M$4.46M$6.49M$5.37M
Current liabilities$2.04M$1.69M$1.26M$2.30M$1.43M$1.76M$1.57M$2.21M
Total liabilities$2.42M$2.49M$2.18M$3.71M$2.64M$3.33M$3.56M$4.55M
Shareholders' equity$3.77M$5.08M$6.40M$7.07M$8.18M$1.13M$2.94M$822,013
Shares outstanding8.70M8.62M50.41M8.33M49.82M31.39M30.84M30.82M
Cash flow statement
Operating cash flow-$1.08M-$1.33M-$3.12M-$1.53M-$1.46M-$56,144$208,049-$2.67M
Capital expenditure$19,659$38,516$40,754$10,607$43,548$3,171$24,416$36,905
Free cash flow-$1.10M-$1.37M-$3.16M-$1.54M-$1.51M-$59,315$183,633-$2.70M
Investing cash flow-$19,659-$38,516-$40,754-$10,607-$43,548-$3,171-$24,416-$36,905
Financing cash flow$345,033$609,622$147,823$66,978$8.23M$245,216-$509,325$2.54M
Depreciation & amortization$41,423$54,450$65,523$64,324$61,015$60,055$65,127$64,127
Stock-based compensation$352,777$342,135$359,255$358,560$316,654$250,170$339,224$340,371

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.